tradingkey.logo


Repligen Corp

RGEN

121.658USD

+1.428+1.19%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
6.84BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Repligen Corp āļšāļĢāļīāļĐāļąāļ—
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™RGEN
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Repligen Corp
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļApr 29, 1986
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Olivier Loeillot
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™1778
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Apr 29
āļ—āļĩāđˆāļ­āļĒāļđāđˆBuilding 1, Suite 100
āđ€āļĄāļ·āļ­āļ‡WALTHAM
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ Global Select Consolidated
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ02453
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ17814499560
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.repligen.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™RGEN
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļApr 29, 1986
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Olivier Loeillot
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
14.31K
-14.90%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason K. Garland
Mr. Jason K. Garland
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Martin D. Madaus, Ph.D.
Dr. Martin D. Madaus, Ph.D.
Independent Director
Independent Director
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
14.31K
-14.90%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
North America
84.59M
50.00%
Europe
59.21M
35.00%
APAC/Other
25.38M
15.00%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 16 āļŠ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 16 āļŠ.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.37%
T. Rowe Price Associates, Inc.
6.10%
Roy T. Eddleman UEO
5.89%
Point72 Asset Management, L.P.
3.40%
āļ­āļ·āđˆāļ™ āđ†
67.25%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.37%
T. Rowe Price Associates, Inc.
6.10%
Roy T. Eddleman UEO
5.89%
Point72 Asset Management, L.P.
3.40%
āļ­āļ·āđˆāļ™ āđ†
67.25%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
59.57%
Investment Advisor/Hedge Fund
25.36%
Hedge Fund
13.00%
Individual Investor
6.39%
Research Firm
2.39%
Pension Fund
2.37%
Bank and Trust
0.68%
Sovereign Wealth Fund
0.59%
Family Office
0.50%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
1028
61.98M
110.32%
-3.21M
2025Q1
1054
62.91M
111.98%
-2.72M
2024Q4
1054
61.13M
109.11%
-3.76M
2024Q3
1046
60.75M
108.48%
-6.10M
2024Q2
1039
61.28M
109.67%
-2.73M
2024Q1
1036
60.56M
108.45%
-5.41M
2023Q4
1062
62.13M
111.29%
-2.30M
2023Q3
1063
61.47M
110.27%
+2.91M
2023Q2
1050
59.01M
105.99%
+1.34M
2023Q1
1061
58.23M
104.67%
+1.01M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
The Vanguard Group, Inc.
5.07M
9.02%
-21.20K
-0.42%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.89M
8.7%
+13.96K
+0.29%
Mar 31, 2025
T. Rowe Price Associates, Inc.
7.52M
13.38%
+427.74K
+6.03%
Mar 31, 2025
Roy T. Eddleman UEO
3.31M
5.89%
-67.50K
-2.00%
Dec 31, 2024
Point72 Asset Management, L.P.
1.12M
1.99%
+197.82K
+21.53%
Mar 31, 2025
State Street Global Advisors (US)
1.69M
3.01%
-2.27K
-0.13%
Mar 31, 2025
Champlain Investment Partners, LLC
1.46M
2.61%
-79.53K
-5.15%
Mar 31, 2025
Sands Capital Management, LLC
1.29M
2.3%
-70.06K
-5.14%
Mar 31, 2025
Invesco Advisers, Inc.
1.60M
2.84%
+768.85K
+93.02%
Mar 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Alger Mid Cap 40 ETF
4.16%
First Trust NYSE Arca Biotechnology Index Fund
3.18%
Invesco Biotechnology & Genome ETF
2.7%
BNY Mellon Innovators ETF
2.6%
iShares Health Innovation Active ETF
1.64%
VanEck Biotech ETF
1.39%
Franklin Genomic Advancements ETF
1.24%
Congress SMid Growth ETF
1.24%
WisdomTree BioRevolution Fund
1%
Pacer US Export Leaders ETF
0.93%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Alger Mid Cap 40 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™4.16%
First Trust NYSE Arca Biotechnology Index Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.18%
Invesco Biotechnology & Genome ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.7%
BNY Mellon Innovators ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.6%
iShares Health Innovation Active ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.64%
VanEck Biotech ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.39%
Franklin Genomic Advancements ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.24%
Congress SMid Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.24%
WisdomTree BioRevolution Fund
āļŠāļąāļ”āļŠāđˆāļ§āļ™1%
Pacer US Export Leaders ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.93%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™